...
首页> 外文期刊>Blood cells, molecules and diseases >Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation
【24h】

Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation

机译:通过多次流量胞质细胞测定骨髓性细胞状细胞序列的枚举,作为同种异体造血干细胞移植后的预后标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmacytoid dendritic cells (pDCs) promote tolerance in solid organ transplants and hematopoietic stem cell transplantation (HSCT). pDCs originate from CD34(+) hematopoietic progenitors. Following allogeneic hematopoietic stem cell transplant (allo-HSCT), pDC reconstitution in the BM and PB gradually attain levels similar to those in healthy individuals. We have investigated the recovery of pDC following allo-HSCT as a means to predict successful marrow engraftment. We retrospectively studied immune reconstitution of pDC in the BM of 48 patients following allo-HSCT for initial diagnoses of leukemia or other malignancies. Multi-parameter flow cytometry was used to detect the CD45(+) CD123(bright) HLA-DR+ CD4(low) pDCs in BM aspirates at 2-14 months (median 6 months) post allo-HSCT. Percentages of pDCs were analyzed along with engraftment, acute graft-versus-host disease (aGVHD), event-free survival, relapse and death over a period of up to 39 months (median 30) following HSCT. We report that higher levels of pDCs in the BM post-HSCT are associated with successful engraftment, less severity of aGVHD, lower relapse rate, higher event-free survival and overall survival (P value 0.05 for all). pDC levels detected at a shorter time interval 2-8 months (median 5 months) following HSCT also showed similar results. We conclude that pDC numbers are associated with HSCT engraftment and overall survival. Flow cytometry offers rapid quantification of pDCs as an early predictor of outcome following HSCT.
机译:血浆骨质特性细胞(PDC)促进固体器官移植和造血干细胞移植(HSCT)的耐受性。 PDC源自CD34(+)造血祖细胞。以下同种异体造血干细胞移植(Allo-HSCT),BM和PB中的PDC重建逐渐达到与健康个体相似的水平。我们已经调查了allo-hsct之后的PDC作为预测成功骨髓植入的手段。我们回顾性地研究了48名患者的BM免疫重建PDC,伴随着allo-HSCT后初步诊断白血病或其他恶性肿瘤。使用多参数流式细胞术检测BM吸气剂在2-14个月(中位6个月)后的BM吸气中的CD45(+)CD123(明亮)HLA-DR + CD4(低)PDC。在HSCT之后,在高达39个月(中位数30)的期间,PDC的百分比与植入,急性移植物与宿主疾病(AGVHD),无事先存活,复发和死亡一起分析。我们报告称BM后HSCT中的更高水平的PDC与成功的植入相关,agvHD的严重程度,降低复发率,更高的无事项存活和总存活(P值<0.05)。在HSCT后2-8个月(中位5个月)在较短的时间间隔内检测到PDC水平也显示出类似的结果。我们得出结论,PDC数字与HSCT植入和整体生存相关。流式细胞术提供PDC的快速定量作为HSCT后结果的早期预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号